Introduction
The urokinase plasminogen activator receptor (uPAR) is a glycosylphosphatidylinositol (GPI) membraneanchored receptor that binds the serine protease urokinase plasminogen activator (uPA). The receptor anchors uPA to the leading edge of migrating cells where the complex stimulates migration by concentrating the proteolytic activity of uPA to the surface of the invading cell. Cell adhesion is also aected by uPAR through its interactions with the extracellular matrix protein vitronectin (Wei et al., 1994; Waltz et al., 1997) and beta-family integrins (Xue et al., 1997; Kindzelskii et al., 1996; Wei et al., 1996) . It also has a role in signal transduction, possibly through interactions with transmembrane molecules such as gp130 or integrins that function as conduits of uPAR-mediated signal transduction (Koshelnick et al., 1997 (Koshelnick et al., , 1999 . That uPAR plays an important role in determining malignancy of most human tumours is based on a large number of experimental studies of both human cancers and model systems and appears to be a negative prognostic marker in a number of cancers (Andreasen et al., 1997 (Andreasen et al., , 2000 .
As the level of uPAR expression critically aects the invasive capacity of a cell, its expression is subject to complex regulation at the levels of translation and transcription (Shetty et al., 1997; Aguirre-Ghiso et al., 1999a) . Many of the growth factor-and cytokineactivated signalling pathways that control uPAR transcription converge on the small GTP-binding protein Ras (Aguirre-Ghiso et al., 1999a). The ras genes (H-ras, N-ras and K-ras) frequently acquire activating mutations in human cancers (Bos, 1998; Hunter, 1997; Yamamoto et al., 1999) and at least HRas and K-Ras have been demonstrated to activate uPAR gene transcription (Aguirre-Ghiso et al., 1999a; Allgayer et al., 1999; Muller et al., 2000) . This suggests a mechanism whereby the activity of oncogenic Ras can be linked to the increased invasiveness of malignant cells through the uPA/uPAR proteolytic system.
Recent studies have demonstrated that Ras stimulates a number of dierent downstream eectors whose activities are essential for its transforming properties (Shields et al., 2000; Yamamoto et al., 1999) . The use of multiple eector pathways by Ras has been demonstrated through the use of constitutively-activated mutants of Ras (V12 H-Ras) that also bear mutations in the eector loop, amino acids 32 ± 40 (White et al., 1995) . These mutants interact with at least three dierent eector molecules; c-Raf, Phosphoinositide 3-kinase (PI3K) and RalGDS. The serine/ threonine kinases c-Raf, activates the ERK (Extracellular Signal-Regulated Kinase) mitogen-activated protein kinase (MAPK) activity that regulates a diverse range of biological events especially gene expression. Phosphoinositide 3-kinase (PI3K) has an emerging role in promoting cell survival (Rodriguez-Viciana et al., 1997; Kaumann-Zeh et al., 1997) . The third and most recently established eector, is the Ral guanine nucleotide exchange factor, RalGDS. RalGDS is a guanine nucleotide exchange factor (GEF) for the small GTPase Ral. Currently, ®ve Ral GEFs have been identi®ed; RalGDS, Rgl, Rlf, Rgr and RalGEF2 that are direct targets for Ras (Bos, 1998; de Bruyn et al., 2000) . They provide a mechanism for Ral activation by extracellular signals via a variety of receptors, including G-protein-coupled receptors and receptor tyrosine kinases (Hofer et al., 1998; Wolthuis et al., 1998a,b) . RalA is one of two highly similar (85% identity) GTPases that constitute a distinct family of Ras-related proteins (Bos, 1997) . The demonstration that dominant-negative mutants of Ras inhibit insulin-and epidermal growth factor-induced activation of Ral has established that Ral de®nes a downstream signalling pathway from Ras (Wolthuis et al., 1998a) . However, Ral can also be activated by Ras-independent mechanisms (Hofer et al., 1998; Wolthuis et al., 1998b) .
The role played by Ral-family proteins in the cell is unclear but they appear to be linked predominantly with cell proliferation and dierentiation (Urano et al., 1996; Wolthuis et al., 1997) . These properties are proposed to result from of the ability of Ral to couple signals from Ras to the induction of gene transcription or to the inhibition of transcription factors like AFX (Murai et al., 1997; Okazaki et al., 1997; Kops et al., 1999; Medema et al., 2000) . The signalling pathway that links Ral activity to transcription is currently unknown.
Our previous work to identify the signalling pathway utilized by oncogenic Ras in activating uPAR gene transcription suggested that RalGDS could have some role in this process (Muller et al., 2000) . In this study, we demonstrate that a constitutively activated RalA mutant, RalA 72L, stimulates transcription from the uPAR promoter and that this requires the presence of at least one of the AP1 sites located 7184 or 770 bp upstream of the major start point of transcription. Activation of transcription is inhibited by a dominantnegative mutant of c-Src, indicating that c-Src is a downstream eector of RalA. We also show that RalA activates the Jun-family members c-Jun and ATF2 in a manner dependent on the phosphorylation sites Ser63 and Ser73 of c-Jun and Thr69 and Thr71 of ATF2. The uPAR is the ®rst example of a gene that can be up-regulated by RalA through an AP1 dependent mechanism.
Results
Differential stimulation of uPAR transcription by Ras effector loop mutants through DNA response elements located within 139 bp of the transcription start site
To locate the Ras-response elements within the promoter, we used luciferase reporter assays to measure expression from a series of uPAR promoter mutants containing 5'-deletions of increasing size. We found that proximal region of the uPAR promoter between 7139 bp and the major transcription start site (+1) was the minimum sequence required to retain the stimulation of transcription by the transforming human H-Ras (V12 H-Ras) (data not shown). Potential binding sites for transcription factors in this region are an AP1/GRE site, a binding site for NF-kB and a number of binding sites for Sp1 (Figure 1a) . To determine if Ras utilized a preferred eector to activate uPAR transcription from this region of the promoter, we used luciferase reporter assays to compare the eects of constitutively activated V12 H-Ras and the eector-loop mutants RasV12/C40, RasV12/G37 and RasV12/S35 on transcription in the cell line NIH3T3 (Figure 1b) . Transcription from the minimal uPAR promoter of 139 bp was stimulated approximately ®vefold by V12 H-Ras and over twofold by Ras 35S and Ras 40C, that utilize Raf-1 and PI3K as their downstream eectors respectively (White et al., 1995) . The most eective stimulation of transcription by a Ras-eector loop mutant was obtained with Ras G37 that utilizes RalGDS as an eector. Stimulation of transcription by this mutant was similar to that obtained using V12 H-Ras. The similar levels stimulated by V12 H-Ras and Ras G37 indicate that Ras promotes expression from this region of the uPAR promoter largely through RalGDS as its immediate eector.
A constitutively-activated mutant of Ral A stimulates transcription from the uPAR promoter
The Ras eector RalGDS, is a guanine nucleotide exchange factor for the Ras-related GTPase RalA. To determine whether RalA is capable of activating uPAR gene transcription, NIH3T3 cells were co-transfected with a luciferase reporter construct containing 1.5 kb of 5' uPAR promoter sequence and V12 H-Ras or RalA 72L, a constitutively-activated mutant of RalA. V12 H-Ras stimulated uPAR transcription ®vefold while RalA 72L resulted in a twofold increase ( Figure  2a ). When the same experiment was performed using a luciferase reporter construct that contained only the 139 bp proximal promoter sequence, the RalA 72L mutant was more ecient than V12 H-Ras in stimulating transcription (Figure 2b ). Although the level of transcription from the 139 bp promoter sequence was lower than that of the larger 1.55 kb uPAR promoter, transcription of the uPAR gene is subject to regulation by a RalA-dependent signal transduction pathway in each case. The lower levels of transcription from the 139 bp promoter may result from the loss of sites further upstream in the uPAR promoter necessary for the assembly or stabilization of basal transcription factors on this TATA-less promoter (Soravia et al., 1995) .
The ability of H-Ras-or RalA-mediated signalling to in¯uence transcription factors recruited to the proximal region of the promoter was supported by electrophoretic mobility shift assay (EMSA) (Figure 2c ). Nuclear extracts from HEK293 cells generated a single complex with a probe spanning +1 to 7210 bp of the uPAR promoter, which is likely to result from the binding of components of the basal transcription machinery. When nuclear extracts from V12 H-Rasor RalA 72L-transfected cells were used, the complex was lost and a new complex formed. This suggests that both H-Ras and RalA cause the additional binding, or exchange, of transcription factors within this region of the uPAR promoter. The data are consistent with those obtained from luciferase reporter assays and clearly indicate that both H-Ras and RalA activate signal induced changes that stimulate transcription of the uPAR gene from response elements within 200 bp of the transcription start site.
RalA activation of uPAR transcription is mediated via AP1 sites at 7184 and 770
The DNA sequence between the major start point of transcription of the uPAR gene and 7139 bp contains potential binding sites for three classes of transcription factor: NF-kB, SP1 and AP1 at an AP1-like site designated AP1/GRE ( Figure 1a ). As Ras-mediated signal transduction has been demonstrated to stimulate the phosphorylation and transcriptional activity of cJun (Smeal et al., 1991; Johnson et al., 1996) , we reasoned that the AP1 binding site at 770 represented the best candidate for a DNA response element that could be involved in H-Ras-dependent, and therefore possibly RalA-dependent, signal transduction. In the context of the uPAR promoter however, an AP1 site at 7184 bp could also contribute to stimulation of transcription by Ras or RalA (Figure 3a ). To determine if either AP1 site is utilized in RalAmediated activation of transcription, DNA probes containing normal or mutated AP1 sites at 770 and 7184 were incubated with nuclear extracts from HEK293 cells. The protein-DNA complexes were analysed by EMSA (Figure 3b ). Complexes were formed in extracts from both untransfected cells and from cells transfected with RalA 72L. As before, the mobility of the complex obtained with nuclear extracts from cells expressing RalA 72L was retarded. The intensity of this band was greatest for the probe that contained two functional AP1 sites and absent with the probe in which both AP1 sites had been mutated. In comparison, mutation of just the AP1 site at 770 bp resulted in a small loss of complex formation while mutation of the site at 7184 bp produced a much greater reduction. These observations indicate that RalA-mediated activation of uPAR gene transcription involves the binding of AP1-transcription factors to both AP1 sites. The marked decrease in complex formation as a result of mutation of the AP1 at 7184 bp suggests that this site is likely to make the greatest contribution to the activation of uPAR transcription.
To clarify whether RalA 72L-mediated signal transduction can utilize either of the two AP1 binding sites in the uPAR promoter to activate transcription, we used PCR-based mutagenesis to inactivate either or both AP1 sites. Luciferase-reporter constructs containing the uPAR promoter region between 750 and 7190 bp with combinations of active and inactive AP1 sites were co-transfected with RalA 72L or V12 H-Ras into HEK293 cells and the levels of luciferase activity determined (Figure 4 ). Promoters that contained both AP1 sequences (770/7184) were inducible by Ras and RalA 72L. These results were consistent with those determined earlier (Figure 2b) . Mutation of the 7184 AP1 site (7184 m) reduced the basal transcriptional activity of the promoter, however both V12 H-Ras and RalA 72L were still able to increase the levels of transcription approximately sixfold, demonstrating that the AP1 site at 770 can mediate Ras-and RalAinduced transcription. The low levels of basal transcription that result from loss of the 7184 AP1 site may be a consequence of its importance in the basal transcriptional activity of the TATA-less uPAR promoter. Mutation of the AP1/GRE site at 770 had little eect on basal transcription levels and was stimulated by RalA 72L and V12 H-Ras to a similar level as the promoter that contained both correct AP1 sequences. Inactivation of both AP1 sites totally abolished any detectable response from RalA 72L or c-Jun and ATF2 are targets of the RalA pathway AP1 is a collective term referring to dimeric transcription factors composed of Jun Fos or ATF proteins that bind to related DNA elements. The sequences of the AP1 binding sites at 7184 and 770 bp dier and they resemble those that would be bound preferentially by c-Jun-containing and ATF-containing AP1 dimers respectively (Hai and Curran, 1991) . As RalA stimulates transcription through both AP1 sites in the uPAR promoter, we tested the ability of RalA to activate c-Jun-and ATF2-dependent transcription. HEK293 cells were co-transfected with plasmid vectors expressing RalA 72L, hybrid proteins consisting of the transactivation domains of either c-Jun or ATF2 fused to the DNA-binding domain of the yeast transcription factor GAL4 and a GAL4-luciferase reporter. RalA 72L activated both GAL-ATF2 and GAL-c-Jun dependent transcription but showed a greater propensity for the activation of c-Jun ( Figure 5 ). Activation of c-Jun-GAL4 and ATF2-GAL4 required the presence of their MAP-kinase phosphorylation sites in their Having established that c-Jun and ATF2 are activated by RalA, we next tried to identify intermediate eectors in the RalA signalling pathway. As c-Jun responded more eectively to RalA 72L stimulation, we attempted to inhibit RalA-induced transcription from the uPAR promoter with a trans-dominant inhibitory mutant of the c-Jun N-terminal kinase (SAPKbK4A). However, co-expression of SAPKbK4A failed to inhibit uPAR transcription, demonstrating that it is not the MAPK that activates c-Jun or ATF2 (Figure 6 ). Similarly, dominant-negative mutants of the extracellular signalregulated kinases ERK1 and ERK2 also failed to inhibit transcription from the uPAR promoter. Indeed, RalA-induced uPAR reporter expression was elevated somewhat in their presence. These results imply that neither ERKs nor SAPKs act downstream of RalA in the activation of c-Jun and ATF2.
As recent evidence suggests that the tyrosine kinase c-Src functions downstream of RalA in the phosphorylation of STAT 3 (Goi et al., 2000) we also explored whether c-Src functions downstream of RalA in the activation of uPAR transcription. A dominant-negative mutant of c-Src was a potent inhibitor of RalA activation of uPAR transcription (Figure 6 ), placing this tyrosine kinase in the signalling pathway between RalA and the activation of uPAR transcription.
Discussion
Increased extracellular protease activity is one of the distinguishing features of metastatic cells and is crucial for the degradation of basement membranes and stromal extracellular matrix that facilitates the invasion of malignant cells. The urokinase plasminogen activator receptor (uPAR) contributes to cell invasion by focusing the serine protease activity of its ligand uPA, to the cell surface. It may also give additional advantages to tumour cells through activating Srcfamily tyrosine kinase, JAK/STAT or MAPK pathways (Tang et al., 1998; Dumler et al., 1998; Nguyen et al., 1999) . It is therefore important to identify the biochemical and molecular mechanisms that regulate the expression of uPAR in normal cells and how these are perturbed in transformed cells. We focused on the activation of uPAR transcription by Ras as it is a point of convergence for diverse extracellular signal-stimulated pathways and frequently suers activating mutations in a wide range of cancers. In addition, the introduction of oncogenic Ras into cells increases extracellular protease activity in general and the expression of uPAR in particular (Westermark and KaÈ haÈ ri, 1999; Lengyel et al., 1995; Jankun et al., 1991; Allgayer et al., 1999; Janulis et al., 1999; Muller et al., 2000) . The work of White et al. (1995) established that the activation of multiple-ras eector pathways is necessary to induce cell transformation. The bestcharacterized eectors of Ras are the serine kinase Raf-1, phosphoinositide 3 kinase (PI3K) and members of the Ral GDS family. Through these eectors, Ras contributes to the transformed phenotype by promoting anchorage-independent growth and by regulating apoptosis (Kauman-Zeh et al., 1997; RodriguezViciana et al., 1997; Yang et al., 1998) . Here we provide evidence that V12 H-Ras or Ras 37G, the eector-loop mutant that activates Ral GDS, and constitutively-activated RalA can activate transcription from the proximal sequence of the uPAR promoter. The recruitment of transcription factors to this region of the uPAR promoter in response to HRas or RalA-dependent signal transduction was also demonstrated by electrophoretic mobility shift analysis. RalA 72L consistently stimulated higher levels of transcription from the 139 bp uPAR-promoter fragment than from the larger 1.55 kb promoter fragment. This suggests RalA-mediated uPAR transcription may be subject to modulation by additional transcription factors in vivo. The presence or activity of these may be regulated through the function of other signal transducing pathways. Interestingly, the uPA gene also appears to be regulated by a RalA-dependent mechanism (Aguirre-Ghisho et al., 1999b) raising the possibility that RalA activity may co-ordinate the expression of uPA with its receptor uPAR. RalA-dependent stimulation of uPAR transcription required the presence of at least one of the AP-1 sites at 770 or 7184 in the uPAR promoter, indicating that transcription is stimulated by a member of the Jun-family and that acts downstream of RalA. The binding site at 7184 (TGAGTCA) resembles that bound preferentially by Jun-Jun and Jun-Fos dimers; while the putative combined glucocorticoid response/AP-1-like element at 770 (TGACTCGC), resembles that preferentially bound by Jun-ATF dimers or ATF homodimers (Hai and Curran, 1991; . This indicates that RalA-dependent signalling could activate AP1 dimers containing combinations of c-Jun or ATF2 proteins. Using hybrid proteins consisting of the activation domains of c-Jun or ATF2 fused to the DNA-binding domain of GAL4, we showed that both ATF2 and c-Jun are indeed activated by RalA signal transduction. This was consistent with the ability of RalA 72L to stimulate transcription from a uPAR promoter fragment that contained alternate functional and mutated AP1 sites and with transcription from the proximal 139 bp uPAR promoter fragment that contains only the AP1/GRE site at 770 bp. Which AP1 site is used in vivo may be determined by the abundance of speci®c AP-1 proteins. ATF2 expression is constitutive unlike that of Jun and Fos whose levels are subject to changes in expression of their genes and changes in their stability . Alternatively, the AP1 site utilized may be dictated by what other transcription factors occupy the promoter (at any particular time).
Having identi®ed the nature of the transcription factors activated by RalA-dependent signal transduction, we next tried to identify some of the downstream components of the signalling pathway through the use of dominant-negative mutants. Dominant-negative mutants of ERK1, ERK2 and SAPKb failed to inhibit RalA activation of uPAR transcription. This ruled out the involvement of members of the Ras-ERK pathway in RalA signalling. It also demonstrated that although RalA signalling can activate c-Jun and ATF2, the failure of the trans-dominant inhibitor SAPKb to inhibit uPAR transcription indicates that JNK is not a prerequisite for the activation of RalA-dependent uPAR transcription. At this stage the identity of the MAPK involved is unclear, however a possible candidate is the MAPK p38. ATF2 is a substrate for p38 and its activation may stimulate uPAR transcription in the presence of the JNK inhibitor SAPKb. We are currently investigating this possibility.
The recent ®nding that c-Src functions downstream of RalA in a signalling pathway that results in the phosphorylation of the transcription factor STAT3 (Goi et al., 2000) prompted us to investigate whether a dominant-negative mutant of c-Src would also inhibit RalA-activated uPAR transcription. We have shown that a dominant-negative mutant of c-Src totally inhibited RalA-dependent uPAR transcription, thereby ®rmly placing c-Src in the signalling pathway between RalA and the activation of transcription. Whether the Src tyrosine kinase is the direct eector of RalA is currently unknown, however the recent ®nding that Src tyrosine kinase activity is directly stimulated through interacting with the Gas or Gai subunits of heterotrimeric G-proteins makes this a distinct possibility (Ma et al., 2000) .
While this paper was under review a paper describing the activation of c-Jun by Ral appeared in print (de Ruiter et al., 2000) . The majority of our ®ndings are in agreement with theirs. We dier however in that we have provided evidence in this paper that RalA signalling can activate both c-Jun and ATF2, while de Ruiter et al. (2000) conclude that Ral signalling leads to the activation of c-Jun only. A possible explanation for these dierent conclusions may be due to dierences in the methods employed for the activation of Ral. More importantly their criterion for the lack of activation of ATF2 by Ral-mediated signal transduction is based on the failure of a dominant-negative RalB-N28 mutant to inhibit ATF2 phosphorylation. In our experiments the RalA signalling pathway was speci®cally activated using a constitutively-activated RalA mutant. In comparison, the activation of Ral by de Ruiter et al. (2000) was initiated upstream of Ral through the treatment of cells with insulin. If insulin activates a signalling pathway that results in the phosphorylation of ATF2 by a Ralindependent mechanism, this pathway would not be inhibited by the dominant-negative RalB-N28 mutant. This would lead to the conclusion made by de Ruiter et al. (2000) that Ral-mediated signal transduction does not activate ATF2.
The identi®cation of a signalling pathway directed towards the activation of uPAR transcription is signi®cant because numerous studies have demonstrated that the downregulation of uPAR is able to switch some human carcinomas into a protracted state of dormancy, or to inhibit the metastasis of others (Aguirre-Ghiso et al., 1999c; Andreasen et al., 1997 Andreasen et al., , 2000 . The elucidation of the complete RalA-dependent signalling pathway may therefore enable the identi®cation of speci®c targets for therapeutic intervention that result in the downregulation of uPAR expression in tumours.
Materials and methods

Plasmids
The construction of the luciferase reporter pGL3-uPAR containing the uPAR-promoter region +9 to 71553 has been described previously (Muller et al., 2000) . The plasmids containing constitutively activated mutants V12H-Ras construction and use of V12 H-Ras and the partial eector mutants V12/G37, V12/C40 and V12/S35 in the vector pSG5 (Stratagene) have also been described (Rodriguez-Viciana et al., 1997) and were generously provided by J Downward (ICRF, London). The Gal4-luciferase reporter vector was constructed by cloning 56Gal4 binding sites and the E4-tata promoter upstream of the luciferase gene in the vector pGL 3 (Promaga). The c-Jun-Gal4 and ATF2-Gal4 fusion proteins were constructed by cloning the activation domains of c-Jun (amino acids 1 ± 166) and ATF2 (amino acids 19 ± 96) downstream of the Gal4 DNA binding domain (amino acids 1 ± 147) in the vector pSG424 (Sadowski and Ptashne, 1989) . The cDNAs encoding c-Jun and ATF2 were a gift from Dr Peter Angel. The transdominant JNK/SAPK inhibitor SAPKb has been described previously (Frost et al., 1997) Cell culture, transfection and measurement of promoter activity
The human embryonic kidney cell line HEK293 were maintained in DMEM (Gibco/BRL) supplemented with 10% FCS. The cells were cultured in a humidi®ed atmosphere of 5% CO 2 . Cells were transfected when they had obtained approximately 70% con¯uency. For each transfection, 2 ± 4 mg of luciferase reporter construct or plasmids encoding constitutively-activate alleles of small GTP-bindingproteins was used. The ®nal amount of DNA used in each transfection of cells in a 90 mm dish was adjusted to a total of 10 mg using pBSII (Bluescript) plasmid (Stratagene). Transfected cells were lysed 48 h post-transfection in 250 mM KCl, 50 mM HEPES pH 7.5, 0.1% NP40, 10% glycerol and luciferase activity was determined. Transfection eciencies were determined by measuring the b galactosidase activity resulting from co-transfection of 1 mg of pCH110 (Amersham Pharmacia Biotec) per plate. When necessary, the amount of luciferase activity in each transfection experiment was normalized to the relative transfection eciency of each experimental point.
Preparation of nuclear extracts
Nuclear extracts were prepared essentially as described by a modi®ed procedure of Dignam et al. (1983) . All solutions were used at 48C and contained 0.2 mM PMSF and 0.5 mM DTT, these were added immediately before use. Nuclear extracts were obtained from 30 ± 50, 90 mm culture dishes of con¯uent HEK 293 cells. The extracts were prepared from cells that had been transfected with plasmids that constitutively expressed activated mutants of ras or ralA. Nuclear extracts from untransfected cells were used as negative control. Cells were harvested in PBS and pelleted by centrifugation at 1850 g for 10 min at 48C. The pellet was washed with PBS and rapidly resuspended in ®ve packed cell volumes (PCV) of hypotonic buer (10 mM HEPES pH 7.9 at 48C, 1.5 mM MgCl 2 , 10 mM KCl). Cells were pelleted by centrifugation at 1850 g for 5 min and supernatant was discarded. The cells were then resuspended in three times the original PCV and incubated on ice for 10 min for swelling to occur before transferring them to a glass homogenizer (Dounce with type B tight pestle). Homogenization was carried out by 10 ± 20 gentle strokes. The nuclei were then pelleted by centrifugation at 3300 g for 15 min. The nuclei were suspended in half the packed nuclear volume (PNV) of low salt buer (10 mM HEPES pH 7.9 at 48C, 1.5 mM MgCl 2 , 0.02 M KCl and a half PNV of high salt buer with 0.8, 1.2, 1.6 M KCl. were added drop wise. The suspensions were homogenized with a further two strokes in the Dounce homogenizer and the nuclear proteins were extracted for 30 min by gentle mixing. Nuclear membranes were precipitated by centrifugation at 25 000 g for 30 min and the supernatant was dialysed against (20 mM HEPES, 100 mM KCl, 20% (v/v) Glycerol, 0.2 mM EDTA) until the conductivity of the sample reached equilibrium that of 100 mM KCl. The extracts were removed from the dialysis bag and centrifuged at 25 000 g for 20 min to remove any precipitate formed during dialysis. The protein concentration was determined by colourimetric assay using Bio-Rad TM DC protein assay kit and stored at 7808C
Electrophoretic mobility shift assay (EMSA)
Binding reactions were carried out in a reaction volume of 20 ml. Each reaction contained 50 mM KCl, 2 mM MgCl 2 , 15 mM HEPES pH 7.9, 2.5 mM EDTA, 2 mM Spermidine, 7% glycerol, 2 mg of BSA, 2.5 mg of herring-sperm DNA, 1 mg of the oligonucleotide poly dI-dC, and between 10 and 30 mg of nuclear-protein extract. Reactions were preincubated for 15 min at room temperature before the addition of 50 ± 100 fmoles (20 000 ± 50 000 c.p.m.) of double-stranded DNA probe. The samples were incubated for a further 10 min at room temperature before analysis on a 5% polyacrylamide gel in TBE buer. Polyacrylamide gels were dried and autoradiographed. EMSAs were analysed using a Fuji FLA-2000 PhosphorImager and Aida 211 data image-analysis software.
Generation of DNA probes
Double-stranded synthetic probes for EMSA were prepared by the polymerase chain reaction (PCR). Each 100 ml reaction contained 20 pmole each of forward and reverse primers, 10 ng of template DNA, 200 mMol of each dNTP and 2.5 mM Mg 2+ ions and 2.5 U of Taq DNA polymerase. The ampli®cation reactions were performed for 30 cycles of 948C (1 min), 688C (1 min) 728C (1 min) followed by a further 10 min extension reaction at 728C for 10 min. The PCR products were puri®ed from agarose gels using a Qiagen TM agarose gel extraction kit. Puri®ed PCR products were 5'-end labeled using T4-polynucleotide kinase and [a-32 P] dCTP as described previously (Sambrook et al., 1989) .
